Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ:ALGS)

7.690 -0.440 (-5.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aligos Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
 
Via Benzinga
Where Aligos Therapeutics Stands With Analysts
Within the last quarter, Aligos Therapeutics (NASDAQ:ALGS) has observed the following analyst ratings: 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows. Interesting Facts About Today's 52-Week Lows: The largest company in terms of market cap... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
 
Via Benzinga
Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)
Single and multiple ascending doses to be evaluated in CHB subjects throughout 2023 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 
From Aligos Therapeutics
Via GlobeNewswire
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here's What You Need To Know
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00. Shares of Aligos Therapeutics are trading up 0.0% over... 
Via Benzinga
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Third Quarter Results November 2, 2022
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics's Return On Capital Employed Overview
According to Benzinga Pro data, during Q2, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $3.69 million. Earnings were up 44.06%, but Aligos Therapeutics still reported an overall loss of $19.92... 
Via Benzinga
Aligos Therapeutics Earnings Preview
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022
From Aligos Therapeutics
Via GlobeNewswire
Aligos Shares Fall Following Commencement Of Initial-Stage Chronic Hepatitis B Study
Aligos Therapeutics, Inc. (NASDAQ: ALGS) has initiated enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis B (CHB) subjects in the ongoing Phase 1b study ALG-000184-201. 
Via Benzinga
Aligos Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Aligos Therapeutics (NASDAQ:ALGS) posted sales of $2.57 million. Earnings were up 5.57%, but Aligos Therapeutics still reported an overall loss of $35.62... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Upgrades 
Via Benzinga
Preview: Aligos Therapeutics's Earnings
Aligos Therapeutics (NASDAQ:ALGS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Aligos... 
Via Benzinga
NASDAQ: ALGS Investor Notice: Investigation over Potential Wrongdoing at Aligos Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation on behalf of investors in Aligos Therapeutics, Inc. (NASDAQ: ALGS) shares over potential wrongdoing at Aligos Therapeutics, Inc. was... 
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2022
Upgrades For E2open Parent Holdings Inc (NYSE:ETWO), Colliers Securities upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $14.58 and... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 92 companies hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.